<?xml version='1.0' encoding='utf-8'?>
<document id="22820896"><sentence text="Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat." /><sentence text=": Orlistat, a lipase inhibitor taken with meals at doses of 60 mg (available over-the-counter) or 120 mg (prescription only) for treatment of obesity, is known to impair the absorption of fat-soluble molecules" /><sentence text=" Dalcetrapib, a modulator of cholesteryl ester transfer protein activity, is a lipophilic thioester prodrug"><entity charOffset="1-12" id="DDI-PubMed.22820896.s3.e0" text="Dalcetrapib" /><entity charOffset="29-46" id="DDI-PubMed.22820896.s3.e1" text="cholesteryl ester" /><entity charOffset="90-99" id="DDI-PubMed.22820896.s3.e2" text="thioester" /><pair ddi="false" e1="DDI-PubMed.22820896.s3.e0" e2="DDI-PubMed.22820896.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22820896.s3.e0" e2="DDI-PubMed.22820896.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22820896.s3.e0" e2="DDI-PubMed.22820896.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22820896.s3.e1" e2="DDI-PubMed.22820896.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22820896.s3.e1" e2="DDI-PubMed.22820896.s3.e2" /></sentence><sentence text=" Lipase-induced and pancreatin-induced hydrolysis of dalcetrapib in biorelevant media in vitro was very efficiently inhibited by orlistat"><entity charOffset="53-64" id="DDI-PubMed.22820896.s4.e0" text="dalcetrapib" /></sentence><sentence text=" Thus, the potential for orlistat to affect the bioavailability of concomitantly administered dalcetrapib was studied in an open-label 2-cohort study in 24 healthy volunteers as follows: single 600-mg doses of dalcetrapib were administered with increasing doses of orlistat (cohort A: 10, 40, 120 mg; cohort B: 20, 60, 120 mg)"><entity charOffset="210-221" id="DDI-PubMed.22820896.s5.e0" text="dalcetrapib" /></sentence><sentence text=" Exposure to the active form of dalcetrapib was more than 50% lower when taken with orlistat 60 mg or 120 mg than when taken alone"><entity charOffset="32-43" id="DDI-PubMed.22820896.s6.e0" text="dalcetrapib" /></sentence><sentence text=" Similar trends were observed with lower orlistat doses (20 mg and 40 mg)" /><sentence text=" Concomitant administration of orlistat also reduced the pharmacodynamic effects of dalcetrapib treatment on cholesteryl ester transfer protein activity"><entity charOffset="84-95" id="DDI-PubMed.22820896.s8.e0" text="dalcetrapib" /><entity charOffset="109-126" id="DDI-PubMed.22820896.s8.e1" text="cholesteryl ester" /><pair ddi="false" e1="DDI-PubMed.22820896.s8.e0" e2="DDI-PubMed.22820896.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22820896.s8.e0" e2="DDI-PubMed.22820896.s8.e1" /></sentence><sentence text=" The interaction exceeds that predicted on the basis of dalcetrapib lipophilicity" /><sentence text=" These findings demonstrate the potential for large interactions between orlistat and esters that undergo de-esterification in the gastrointestinal tract, independent of lipophilicity" /><sentence text="" /></document>